PAVM
PAVmed Inc.
NASDAQ · Healthcare · Medical - Devices · US
$2.25
−6.64%Year over year
Reported trailing growth
- Revenue
- -89.0%
- EBITDA
- —
- EBIT
- +0.8%
- EPS
- —
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- +328.6%
- EBITDA
- +21.6%
- EPS
- +87.4%
Three-year CAGR
- Revenue
- -42.7%
- EBITDA
- —
- EBIT
- +51.0%
- Net income
- -99.0%
- EPS
- —
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026